{
    "id": 20873,
    "fullName": "MAP2K1 F53L",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MAP2K1 F53L does not lie within any known functional domains of the Map2k1 protein (UniProt.org). F53L results in activation of Map2k1 as indicated by increased Erk and Mek phosphorylation in cell culture (PMID: 25164765, PMID: 29483135) and also demonstrates resistance to some Mek and Braf inhibitors (PMID: 29753091).",
            "references": [
                {
                    "id": 11332,
                    "pubMedId": 29483135,
                    "title": "Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29483135"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                },
                {
                    "id": 5144,
                    "pubMedId": 25164765,
                    "title": "Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25164765"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5604,
        "geneSymbol": "MAP2K1",
        "terms": [
            "MAP2K1",
            "CFC3",
            "MAPKK1",
            "MEK1",
            "MKK1",
            "PRKMK1"
        ]
    },
    "variant": "F53L",
    "createDate": "04/11/2016",
    "updateDate": "07/01/2018",
    "referenceTranscriptCoordinates": {
        "id": 173370,
        "transcript": "NM_002755",
        "gDna": "chr15:g.66435103T>C",
        "cDna": "c.157T>C",
        "protein": "p.F53L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14260,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 F53L displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14287,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 F53L displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 658,
                "therapyName": "AZD8330",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14280,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 F53L displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6453,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F53L demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5602,
                    "pubMedId": 26582713,
                    "title": "Identification of an \"Exceptional Responder\" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582713"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10311,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 F53L in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 3505,
                "therapyName": "Cetuximab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14266,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 F53L displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 2617,
                "therapyName": "PD98059",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14273,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 F53L displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14252,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Map2k1 F53L displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 F53L conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 21379,
                "profileName": "MAP2K1 F53L"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21379,
            "profileName": "MAP2K1 F53L",
            "profileTreatmentApproaches": [
                {
                    "id": 8526,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "MAP2K1 F53L"
                },
                {
                    "id": 8527,
                    "name": "MEK1 Inhibitor",
                    "profileName": "MAP2K1 F53L"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 173370,
            "transcript": "NM_002755",
            "gDna": "chr15:g.66435103T>C",
            "cDna": "c.157T>C",
            "protein": "p.F53L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 173371,
            "transcript": "XM_017022411",
            "gDna": "chr15:g.66435103T>C",
            "cDna": "c.157T>C",
            "protein": "p.F53L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}